Laxxon Medical Announces Positive Pilot PK Study Results for Advanced Levodopa/Carbidopa Asset for Parkinson’s Disease, LMX.5 Laxxon Medical Tue, Feb 4, 2025, 9:00 AM 3 min read ...
The LXM.5 pilot study reveals an 80% bioavailability increase compared to competing products combining levodopa and carbidopa. The study additionally shows sustained and smooth levodopa levels in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback